MPN

One scientific development can lead to many more for patients with myeloproliferative neoplasms, a type of rare blood cancer, according to an expert.

After a patient is diagnosed with a rare disease such as a myeloproliferative neoplasm, learning about their condition and seeking expert clinicians can help put their mind at ease.

Earlier treatment with Jakafi showed promise in both improving survival and symptom burden in certain patients with myelofibrosis, though physicians often delay Jakafi treatment.

If approved by the FDA later this year, momelotinib could fulfill an area of unmet need for patients with myelofibrosis, according to an expert.

I was shocked when I was diagnosed with a myeloproliferative neoplasm, and have dedicated myself to learning about the disease since.

Watch Dr. Andrew Kuykendall, from the Mofitt Cancer Center, discuss second-line treatments and beyond for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Watch to Dr. Naveen Pemmaraju, from The University of Texas MD Anderson Cancer Center, discuss frontline treatment options for patients with myelofibrosis during the CURE® Educated Patient® MPN Summit.

Key opinion leaders highlight different testing and workup methods involved in making an accurate diagnosis of myeloproliferative neoplasms.

Experts Rami Komrokji, MD, and Ruben Mesa, MD, define myeloproliferative neoplasms (MPNs) and explain differences between essential thrombocythemia (ET), polycythemia vera (PV), and myelofibrosis (MF).

Watch Dr. Jamile Shammo and Dr. John Mascarenhas answer questions about polycythemia vera during the CURE Educated Patient MPN Summit.

Research efforts will improve the lives of patients with myelofibrosis, though those advancements may take years to come, an expert said.

Watch Dr. John Mascarenhas, from the Icahn School of Medicine at Mount Sinai, discuss future treatments for polycythemia vera, during the CURE Educated Patient MPN Summit.

Watch Dr. Jamile M. Shammo, from Northwestern University Feinberg School of Medicine, discuss current treatment options in polycythemia vera during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron Gerds and Dr. Douglas Tremblay answer questions about essential thrombocythemia during the CURE Educated Patient MPN Summit.

Watch Dr. Douglas A. Tremblay, from Mount Sinai, discuss treatment for essential thrombocythemia during the CURE Educated Patient MPN Summit.

Watch Dr. Aaron T. Gerds, from Cleveland Clinic Taussig Cancer Institute, discuss essential thrombocythemia risk during the CURE Educated Patient MPN Summit.

Patients with myelofibrosis should be open about their treatment goals with their providers, and potentially consider getting a second opinion or participating in a clinical trial, one expert says.

Treatment with the novel drug GB2064 was associated with decreased fibrosis in patients with myelofibrosis, a type of blood cancer, according to findings from an ongoing phase 2 trial.

A decision to rename myeloproliferative neoplasms led to a plethora of developments in a space where there was once little interest.

A clinical trial recently kicked off, analyzing the combination of imetelstat plus Jakafi for the treatment of myelofibrosis, a type of rare blood cancer.

The Food and Drug administration has approved Pemazyre for patients with relapsed or refractory myeloid/lymphoid neoplasms (MLNs) with an FGFR1 rearrangement.

Treatment with Ayvakit was associated with promising outcomes in patients with mastocytosis, according to findings from the PIONEER trial.

The FDA has set a date to decide whether or not to approve momelotinib for myelofibrosis, a rare type of blood cancer.

Sierra Oncology noted in a company-issued press release that if momelotinib is approved by the FDA that they anticipate making the drug available to patients with myelofibrosis next year.

It is incredibly important that patients with MPNs inform their health care team of any symptoms they are experiencing, according to an expert from The Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center.